Equality between age-groups.

Dennis McKerlie

Home/Archive/PubMed

PubMed · 11652071

Equality between age-groups.

Dennis McKerlie

View original source ↗Export metadata ↓

Abstract

The first part of the article considers what proponents of the most familiar egalitarian moral theories would say about age-group inequality. I claim that these theories have intuitively objectionable consequences. The second part explains and criticizes a theory of justice formulated specifically for age-groups: Norman Daniels' prudential lifespan account. In the third part I explain two views that seem to me to give a better account of justice between the young and the old.

Explore related subjects

Age Factors Aged Delivery of Health Care Ethics Health Care Rationing Humans Patient Selection Prejudice Public Policy Quality of Life Resource Allocation Social Justice Social Values Analytical Approach Health Care and Public Health Philosophical Approach Journal Article

Keep this discovery

Explore connections, maps & timelines

BibTeX RIS

Dennis McKerlie. 1992. Equality between age-groups.. https://pubmed.ncbi.nlm.nih.gov/11652071/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2003

Cataract blindness--challenges for the 21st century.

Cataract prevalence increases with age. As the world's population ages, cataract-induced visual dysfunction and blindness is on the increase. This is a significant global problem. The challenges are to prevent or delay cataract formation, and treat that which does occur. Genetic and environmental factors contribute to cataract formation. However, reducing ocular exposure to UV-B radiation and stopping smoking are the only interventions that can reduce factors that affect the risk of cataract. The cure for cataract is surgery, but this is not equally available to all, and the surgery which is available does not produce equal outcomes. Readily available surgical services capable of delivering good vision rehabilitation must be acceptable and accessible to all in need, no matter what their circumstances. To establish and sustain these services requires comprehensive strategies that go beyond a narrow focus on surgical technique. There must be changes in government priorities, population education, and an integrated approach to surgical and management training. This approach must include supply of start-up capital equipment, establishment of surgical audit, resupply of consumables, and cost-recovery mechanisms. Considerable innovation is required. Nowhere is this more evident than in the pursuit of secure funding for ongoing services.

Age Factors↗

PubMed2002

Risk factors for repeat-breeder syndrome in New South Wales dairy cows.

A retrospective case-control study involving 1041 cow lactations from 10 commercial dairy herds in Australia determined relationships between biographic, production, reproductive and disease factors and repeat-breeder syndrome (RBS) (conception to greater than two inseminations). The study population was stratified into primiparous- and multiparous-cow sub-groups and logistic regression was used. Effects of herd were examined by including this variable alternatively as a fixed and a random effect. In the primiparous-cow fixed-effect model, the risk of RBS was increased with post-calving metritis, stillbirth, and with increasing days taken to reach peak milk yield, and reduced following dystocia. An inverted U-shaped relationship with total milk-solids percentage at the time of first service was detected. In the multiparous-cow fixed-effect model, the risk of RBS was increased in cows with chronic metritis, cystic ovarian disease (COD), in cows of parity >5 and in cows that were sub-fertile in the previous lactation. Increasing days to first recorded heat (DFH) reduced risk of RBS and a non-linear relationship with average 120-day milk-protein percentage was found. When herd was fitted as a random effect, stillbirth and 120-day average milk-protein percentage were no longer significant in the primiparous and multiparous models, respectively. The study emphasises the need to control appropriately for the clustering effect of herd and supports the need to minimise periparturient disease and improve nutrient balance to achieve optimal fertility in dairy herds.

Age Factors↗

PubMed2002

Sildenafil for male erectile dysfunction: a systematic review and meta-analysis.

OBJECTIVE: To determine the efficacy and safety of sildenafil citrate in the treatment of male erectile dysfunction. DATA SOURCES: The MEDLINE, HealthSTAR, Current Contents, and Cochrane Library databases (January 1, 1995, through December 31, 2000); bibliographies of retrieved articles and review articles; conference proceedings abstracts; the Food and Drug Administration Web site; and the manufacturer. STUDY SELECTION: Trials were eligible if they included men with erectile dysfunction, compared sildenafil with control, were randomized, were of at least 7 days' duration, and assessed clinically relevant outcomes. DATA EXTRACTION: Two reviewers independently evaluated study quality and extracted data in a standardized fashion. DATA SYNTHESIS: Twenty-seven trials (6659 men) met the inclusion criteria. In results pooled from 14 parallel-group, flexible as-needed dosing trials, sildenafil was more likely than placebo to lead to successful sexual intercourse, with a higher percentage of successful intercourse attempts (57% vs 21%; weighted mean difference, 33.7; 95% confidence interval [CI], 29.2-38.2; 2283 men) and a greater percentage of men experiencing at least 1 intercourse success during treatment (83% vs 45%; relative benefit increase, 1.8; 95% CI, 1.7-1.9; 2205 men). In data pooled from 6 parallel-group, fixed-dose trials, efficacy appeared slightly greater at higher doses. Treatment response appeared to vary between patient subgroups, although relative to placebo, sildenafil significantly improved erectile function in all evaluated subgroups. In trials with parallel-group design and flexible dosing, men randomized to receive sildenafil were less likely than those receiving placebo to drop out for any reason and no more likely to drop out due to an adverse event or laboratory abnormality. Specific adverse events with sildenafil included flushing (12%), headache (11%), dyspepsia (5%), and visual disturbances (3%); all adverse events were significantly less likely to occur with placebo. Sildenafil was not significantly associated with serious cardiovascular events or death. CONCLUSIONS: Sildenafil improves erectile function and is generally well tolerated. Treatment response seems to vary between patient subgroups, although sildenafil has greater efficacy than placebo in all evaluated subgroups.

Age Factors↗